Strong margins mask growth miss; execution risk on 2030 vision

Q1 standalone domestic ₹146 Cr, +16.2% YoY (vs 20%+ guidance)

Q1 standalone international ₹281.8 Cr, +10% YoY (vs 15%+ guidance)

Europe Q1 organic growth 17.6% (on target; vs -prior-year laggard status)

Standalone EBITDA ₹120.8 Cr on ₹431 Cr revenue = 28.0% (100 bps above range due to price hikes + inventory gains)

Consolidated EBITDA ₹126.7 Cr on ₹525.4 Cr revenue = 24.1% (within range)

Renal down ₹43.2 Cr, -3.8% YoY; recovery contingent on anti-dumping duty (20% injury margin claimed, decision expected by year-end)

Q1 domestic +16.2% vs >20% FY27 guidance. Mgmt attributes to Q1 seasonal weakness and price hike absorption; expects recovery Q2+. No numeric guidance cut, but trajectory downside noted.

Q1 international +10% vs >15% guidance. Middle East -32% due to West Asia crisis logistics. Europe +17.6% organic recovered (vs prior laggard). Overall organic export +12.4%, below target.

Q1 renal -3.8% to ₹43.2 Cr. Chinese dumping via ASEAN FTA zero-duty pressure. Anti-dumping probe initiated; recovery to +15–18% contingent on government decision.

Standalone gross margin 71.5% in Q1 will normalize to 67–69% as inventory gains fade and price hikes pass through. Q1 EBITDA margin 28% above 25–27% guidance; expect mid-to-high range going forward.

PendraCare/Citieffe cross-selling synergies now expected FY28+ (was previously expected to accelerate FY27). Regulatory approval delays cited.

Q1 is historically lowest; recovery expected Q2 onwards. Price hike taken at start of year caused initial slowdown; momentum expected to build. Guidance maintained at ₹1,900–2,000 Cr standalone.

Organic + inorganic expansion. Brazil expansion funds (new small acquisition in place). Technologies in cardiology/oncology/orthopedics targeted. Capex for 2 new plants (Faridabad, Noida). Asset turns 1.2–1.4x to continue.

Infusion therapy domestic grew 20%+. Cardiology & critical care (newer segments) grew meaningfully. Renal de-growth of -3.8% offset gains.

Shipping schedule still disrupted; hard to find containers. Demand intact; orders piling at ports. Ships not calling. Disruption continues; hoping for easing in coming weeks.

Integration on track. Synergies identified (cost, R&D, sales). Cross-selling expected FY28+ due to CDSCO approval cycles for India market entry.

18% CAGR needed. Currently 80% organic, 20% inorganic; expect similar run-rate (14–15% organic, 3–4% inorganic). Margins 25–27% maintained (upper end by year-end); will improve as scale happens but reinvested.

Europe (new customer acquisitions, recovery on track). Southeast Asia doing well. U.S. fluid situation. Middle East high-upside once resolved (20–25% potential). 25 new CE-marked products coming in 3–4 months.

De-growth due to Chinese dumping via ASEAN FTA. Antidumping probe initiated; 20% injury margin claimed. Decision expected next few months by year-end. New renal head (Abhimanyu Hooda) hired. Expecting 15–18% growth by year-end; possibly 20% depending on probe outcome.

Standalone should normalize to 67–69%. Consolidated 71–72% (due to acquisitions' higher margins). Q1 elevated by inventory gains + price hikes.

Yes. Consolidated EBITDA guided 23–25%; Q1 delivered 24.1%. OpEx higher due to acquisition nature and scaling. Maintaining guidance.

PendraCare 20% Middle East exposed; currently de-growing (West Asia crisis). Citieffe growing mid-to-high single digits. Long-term potential: high single-digit organic growth; mid-teens with synergies, assuming geopolitical resolution.

Standalone: No debt, only ₹250 Cr working capital revolving credit. PendraCare: No long-term debt. Citieffe: EUR 9 million total, EUR 1.5–2 million annual repayment.

PolyMed standalone will grow faster than subsidiaries directionally. Overall 2x target on consolidated basis. Standalone will outpace acquired entities' growth rates.

Mix of price hikes, product mix, inventory gains. Guiding 68–69% gross margin standalone going forward. Some Q2 correction expected vs Q1.

Current duty 10%. U.S. exposure small (~USD 3.5–4 million exports). Not a major issue if tariffs rise.

Manufacturing company; blue-collar workers are variable. Rest fixed (subject to productivity). Mix of both in staff. Tough to give ballpark on call.

Expand within existing therapies. These are very new (started 1–2 years ago). Regulatory pathways take 2–3 years for Class III devices. Enough on plate. No new therapies substantially expected next few years.

Market is huge. Many uncovered therapies (peripheral vascular, neurology, urology, endosurgery, gastroenterology). Significant potential; will build portfolio over time.

Europe growth back 17% YoY. Cash conversion cycle: 140 days in March, still ~140 days now. May improve as global situation normalizes, oil prices stabilize.

PolyMed has 399 global patents. Market leader in infusion/other therapies. Products going to 125 countries based on performance. Differentiation in clinical use (doctor/clinician sees it), not just catalog view. Launching 25–30 products/year.

Faridabad/Palwal: Online by March 2027 (Q4 FY27). Focus orthopedics/transfusion, plus infusion capacity. Noida: Online Q1 FY28. Focus cardio expansion.

Q1 delivered ₹525.4 Cr (on track for ~23% of annual). Organic growth 12.4% suggests base met; needs Q2–Q4 acceleration to hit 12.3%.

Q1 ₹431 Cr at 12.3% growth. Domestic >20%, international >15% sub-targets not met in Q1; recovery expected Q2–Q4.

Q1 margin 100 bps above range due to price hikes + inventory gains (one-time). Expect normalization to mid-to-high range (26–27%) going forward.

On track. Higher-margin acquisitions lifting consolidated profile. Maintained within range.

Q1 standalone 71.5% inflated by inventory/price hikes; normalizes to 67–69%. Consolidated 73.4% (acquisitions' mix benefit).

Two new plants under construction: Faridabad/Palwal (online Mar 2027), Noida (online Q1 FY28). Asset turns 1.2–1.4x to continue.

West Asia conflict causing 32% de-growth in Middle East Q1. Shipping schedule disrupted; orders piling at ports. Demand intact but unable to ship. Logistics costs up 2–3x over 6 months. Timeline for resolution uncertain.

Renal business -3.8% in Q1 due to Chinese dumping via ASEAN FTA zero-duty imports. Conscious choice to raise prices rather than defend volume. Company has filed antidumping application; injury margin of 20% claimed. Govt decision expected by year-end.

PendraCare (20% Middle East exposed, currently de-growing) and Citieffe (growing mid-to-high single digits) synergies deferred to FY28+ due to CDSCO approval timelines for cross-sell and manufacturing shift to India. Near-term accretion limited.

Q1 domestic +16.2%, international +10% both miss FY27 targets (>20%, >15%). Management attributes to Q1 seasonality but needs sustained acceleration Q2–Q4 to restore trajectory. If growth doesn't recover, FY27 guidance may face downside risk.

U.S. tariff uncertainty (currently 10% duty). Small direct exposure (USD 3.5–4 million). Hard currency availability in some export markets impacting working capital cycle. Oil price volatility cited.